Price Chart
Key Statistics
Market Cap(EOD)598.88M
Enterprise Value528.45M
P/E Ratio (TTM)-24.80
P/B Ratio (TTM)12.53
P/S Ratio (TTM)0.00
Earnings Yield (TTM)-4.03%
ROE (TTM)-69.78%
ROIC (TTM)-23.67%
Net Profit Margin (TTM)N/A
Dividend Yield (TTM)N/A
Payout Ratio (TTM)N/A
Debt/Equity (TTM)0.00
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.